Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25669477 | 0.85 | RAB9A (0.39) | CSNK2A1KMT2AMEN1ALDH1A1HTT | |
| SCHEMBL1549076 | 0.84 | CSNK2A1 (0.53) | CSNK2A1KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL623349 | 0.82 | CSNK2A1 (0.52) | CSNK2A1KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL30388279 | 0.81 | CSNK2A1 (0.50) | CSNK2A1KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL15462885 | 0.81 | CSNK2A1 (0.50) | CSNK2A1KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL4135507 | 0.81 | CSNK2A1 (0.50) | CSNK2A1KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL7774557 | 0.81 | CSNK2A1 (0.50) | CSNK2A1KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL2336414 | 0.81 | SRC (0.54) | CSNK2A1KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL20943211 | 0.81 | CSNK2A1 (0.50) | CSNK2A1KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL25669476 | 0.80 | NR4A2 (0.46) | ALDH1A1KDM4EHTTCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903979-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS INC (US) | 2020-08-19 | — | — | EP | claimed |
| EP-3303415-B1 | VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF | ALCON INC (CH) | 2022-12-28 | — | — | EP | disclosed |
| US-10324311-B2 | Visible-light photoinitiators and uses thereof | NOVARTIS AG (CH) | 2019-06-18 | — | — | US | disclosed |
| EP-3303415-A1 | VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF | Novartis AG (CH) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016193912-A1 | VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF | NOVARTIS AG (CH) | 2016-12-08 | — | — | WO | disclosed |
| US-20160357031-A1 | VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF | ALCON INC. (CH) | 2016-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10324311-B2 | Visible-light photoinitiators and uses thereof | SIRT5, IK, IGLV6-57 | CSNK2A1 3342/4885KMT2A 1052/4885MEN1 1837/4885 |
| US-20160357031-A1 | VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF | SIRT5, IK, IGLV6-57 | CSNK2A1 3342/4885KMT2A 1052/4885MEN1 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.